Spinraza sales lift Biogen revenues

Biogen Inc. (NASDAQ:BIIB) said Jan. 29 that growing sales of spinal muscular atrophy therapy Spinraza nusinersen helped the company to a 10% increase in 2018 revenues. The company also disclosed

Read the full 309 word article

User Sign In